Disease · MONDO_0005080

portal hypertension

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. portal hypertension. Diseases, record MONDO_0005080. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005080

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: portal hypertension; Open Targets
Open Targets ID: MONDO_0005080; Open Targets
Other names: Cruveilhier Baumgarten Syndrome, Hypertension, Portal, Hypertensions, Portal, PHT - Portal hypertension, Portal Hypertensions, Portal hypertension (disorder), Syndrome, Cruveilhier-Baumgarten; Open Targets
Disease Ontology: DOID:10762; Disease Ontology
MeSH: D006975; MeSH
NCI Thesaurus: C3119; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 28 drugs, from ClinicalTrials.gov; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARVEDILOL	CHEMBL723	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
SIMVASTATIN	CHEMBL1064	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NORFLOXACIN	CHEMBL9	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALVERINE	CHEMBL253371	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALVERINE CITRATE	CHEMBL1408594	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
SAPROPTERIN	CHEMBL1201774	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AVENCIGUAT	CHEMBL5314503	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TERLIPRESSIN	CHEMBL2135460	Protein	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets99

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
ADRB1	Adrenergic receptor beta	2	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor beta	2	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
AVPR1A	Vasopressin V1 receptor	2	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Phase 2	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin V1 receptor	2	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Phase 2	https://conductscience.org/library/genes/553	Drugs and targets
AVPR2	Vasopressin V2 receptor	2	Vasopressin V2 receptor binding agent; Vasopressin receptor agonist	Phase 2	https://conductscience.org/library/genes/554	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
ADRB3	Adrenergic receptor beta	1	Adrenergic receptor beta antagonist	Phase 3	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 99

See all 99 targets

Trials40

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02462967	Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis	Phase 2	162	2020-10-08	Hypertension, Portal	BELAPECTIN	Its record names the disease	ClinicalTrials.gov
NCT05282121	A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)	Phase 2	90	2025-04-29	Liver Diseases, Hypertension, Portal	AVENCIGUAT, EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT05161481	A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)	Phase 2	80	2025-06-15	Hypertension, Portal	AVENCIGUAT	Its record names the disease	ClinicalTrials.gov
NCT01640964	An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension	Phase 2	47	2016-01-20	Compensated Cirrhosis and Portal Hypertension	SERELAXIN, TERLIPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT02802228	Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients	Phase 2	30	2022-01-19	Portal Hypertension, Liver Cirrhosis	IFETROBAN	Its record names the disease	ClinicalTrials.gov
NCT02230683	A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension	Phase 2	23	2016-12-21	Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension	EMRICASAN	Its record names the disease	ClinicalTrials.gov
NCT06082843	A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly	Phase 2	22	2025-06-12	Hypertension, Portal, Liver Cirrhosis	AVENCIGUAT	Its record names the disease	ClinicalTrials.gov
NCT00737594	Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension	Phase 2	9	2016-03-16	Portal Hypertension	COBIPROSTONE	Its record names the disease	ClinicalTrials.gov
NCT02465645	To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.	Not applicable	220		Cirrhosis With Esophageal Varices	CARVEDILOL, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT06470386	The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis	Phase 2/3	178		Hypertension, Portal	ALVERINE CITRATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 40

See all 40 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ifetroban vs Placebo: deaths from any cause	0 of 20	0 of 10	30	NCT02802228	Trial comparisons
Ifetroban vs Placebo: serious adverse events	2 of 20	1 of 10	30	NCT02802228	Trial comparisons
Avenciguat vs Placebo: Occurrence of Discontinuation Due to Hypotension or Syncope During the 8-week Treatment Period	0 of 10	0 of 12	22	NCT06082843	Trial comparisons
Avenciguat vs Placebo: Occurrence of CTCAE Grade 3 (or Higher) Hypotension or Syncope Based on Investigator Judgement During the 8-week Treatment Period	0 of 10	0 of 12	22	NCT06082843	Trial comparisons
Avenciguat vs Placebo: deaths from any cause	0 of 10	0 of 12	22	NCT06082843	Trial comparisons
Avenciguat vs Placebo: serious adverse events	2 of 10	0 of 12	22	NCT06082843	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31812510	RESULT	1	PubMed
41674894	DERIVED	1	PubMed
37095557	DERIVED	2	PubMed
32629127	DERIVED	1	PubMed
32580978	DERIVED	1	PubMed
32164767	DERIVED	1	PubMed
32113581	DERIVED	1	PubMed
32079861	DERIVED	1	PubMed
29578250	DERIVED	1	PubMed
28245243	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005080

GET https://conductscience.org/api/diseases/v1/MONDO_0005080/drugs?page=2

API reference For AI assistants